This news round-up covers our latest news and updates from September and October. It has been a busy month for Inaphaea, with our parent company ValiRx signing several agreements with CROs and biotechs around the world as we move forward with our growth plans.
News round-up: Autumn 2024
Evaluation and commercial use agreement with BioReperia
In late August, we announced the execution of an evaluation and commercial use agreement with Swedish contract research organisation (CRO) BioReperia to provide Inaphaea’s patient derived cells for evaluation and commercial use in BioReperia’s unique in vivo ZTX platform.
This agreement represents a great step forward in commercialising Inaphaea’s primary asset – our patient derived cell bank. Read more.
Evaluation and commercial use agreement with DLOC
To kick off September, we confirmed the execution an agreement with UK-based DLOC Biosystems Holdings Ltd (DLOC) to provide Inaphaea’s PDCs for evaluation and commercial use in DLOC’s state-of-the-art organ-on-a-chip technology.
The contract initially focuses on establishment of up to four glioblastoma and one triple negative breast cancer in-vitro 3D tumour model which will then be offered for commercial services by DLOC and Inaphaea. Learn more.
Co-marketing agreement with Spanios LLC
We then signed a co-marketing agreement with US CRO Spanios to provide Inaphaea’s high throughput drug screening services using its PDC as a precursor to Spanios’ proprietary Patient Derived Tumoroids (PDT).
This deal with is the first co-marketing arrangement for Inaphaea in the US and demonstrates the synergy of our PDC approach for rapid and economic screening of larger numbers of drug candidates before transferring lead candidates into Spanios’ lower throughput but higher complexity, ex-vivo models. Find out more.
Evaluation and commercial use agreement with Xenopat
Inaphaea’s third evaluation and commercial use agreement in September was confirmed with Spanish CRO Xenopat. The deal will see Inaphaea provide our PDCs for evaluation and commercial use in Xenopat’s in vivo Xenograft platform and provides access to Inaphaea’s 470+ PDCs which can be added at any time.
This deal marks another milestone in the commercialisation of Inaphaea’s PDC bank and in expanding the range of in-vivo models available for commercial use. Continue reading here.
Co-marketing agreement with Ignota Labs
We were also pleased to confirm an agreement with emerging UK drug turnaround biotech Ignota Labs to collaborate on the exchange of data from our biobank to generate insights, co-develop new assets, and explore joint business opportunities, including grant funding. The agreement builds upon an initial collaboration partnership between Ignota and Inaphaea.
Ignota Labs will analyse data from Inaphaea’s biobank to develop in-silico models. These models will help identify new oncology assets, with plans to co-develop them through Inaphaea’s tCRO® services and Ignota’s platform.
This agreement leverages the datasets from Inaphaea’s biobank to further develop Ignota Labs’ in-silico capabilities, benefitting our early-stage evaluation as well as providing an exciting new AI approach to asset discovery. Read more.
Co-marketing agreement with BioRep
On 7 October, Inaphaea confirmed the execution of a co-marketing agreement with Italian biobanking service provider BioRep, a Sapio Group company, to provide Inaphaea’s high throughput drug screening services and PDCs to BioRep’s network of clients. BioRep will provide backup samples storage and logistic services, in addition to molecular biology services into mainland Europe.
This deal BioRep expands our reach into Europe whilst providing backup storage solutions. Read the full story here.
Get in touch
To discuss any of our updates or learn how our cell-based assays can benefit your project, please contact us here.